研究では、低リスク前立腺がんに対する積極的監視の選択に関連する要因を評価しています

Low-risk prostate cancer is less likely to spread or affect survival, so experts and guidelines recommend active surveillance. This includes regular monitoring, which can help avoid or delay treatments such as surgery or radiation therapy and life-changing complications. A new study focuses on underserved Black patients who have been underrepresented in previous studies and examines the uptake of active surveillance and chooses this management strategy over surgery or radiation therapy. We evaluated factors associated with The findings will be published online by Wiley in his CANCER, a peer-reviewed journal of the American Cancer Society.

In the study, called the "Prostate Cancer Treatment Options Study," Jingping Xu, MD, PhD, and MSc, Wayne State University, analyzed data from cancer registries in metro Detroit, Michigan, and Georgia, and analyzed data from related patient Focused on self-reported information. Participants were black and white patients newly diagnosed with low-risk prostate cancer between 2014 and 2017.

Of the 1,688 patients, 57% chose active surveillance over other treatments (51% of black patients and 61% of white patients). After controlling for other influencing factors, the strongest factor determining the implementation of active surveillance was the urologist's recommendation to select this option. Other factors associated with the decision to undergo active surveillance include shared patient and physician treatment decisions and greater knowledge about prostate cancer. Participants living in Metro Detroit were also more likely to choose active surveillance than those living in Georgia.

offline, if a man is strongly influenced by the desire to achieve a "cure," or expects treatment to "live longer," or believes that a low-risk prostate cancer diagnosis is more dangerous. When aware, men were less likely to attempt active surveillance. "Severe."

Education and intervention for patients, especially urologists, that address these factors may increase the use of recommended active surveillance for patients with low-risk prostate cancer.